EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Immune–epidermal dual targeting in psoriasis: emerging technologies and translational therapeutic strategies

Meijun Liu, Pinzhi Dong, Cong Yang, Xiaorong Xu, Yingnong Wu, Jin Chen, Wenjie Tian, Haiyan Wang, Junmin Luo, Ming Qin

British Journal of Dermatology · 2026-09-08

DOI: 10.1093/bjd/ljag390 ↗
AbstractBibliografische Angaben

Abstract

Abstract Although immune-targeted therapies, particularly agents targeting the interleukin (IL)-23/IL-17 axis, have markedly improved short-term disease control in psoriasis, inadequate responses in a subset of patients and relapse after treatment discontinuation remain unresolved challenges. One possible reason is that immune-centred therapies may not fully address the active contribution of epidermal keratinocytes to inflammatory amplification and disease persistence. In this review, we integrate immune-driven inflammation and epidermal amplification mechanisms from a loop- and network-based perspective, and ­propose an immune–epidermal dual-targeting framework centred on proinflammatory feedback between immune cells and keratinocytes. We systematically summarize three potential implementation routes: combination therapy, single-agent dual targeting and blockade of bridging nodes within immune–epidermal feedback circuits. We further discuss the potential roles and realistic boundaries of artificial intelligence and multi-omics analysis, organoids and engineered skin models, and precision local delivery technologies in target discovery, mechanistic validation and therapeutic translation. Importantly, this framework is not intended to replace existing therapeutic paradigms, but rather to refine their mechanistic interpretation and extend future therapeutic strategies. It may provide additional translational opportunities for stratified, stage-specific and precision management of psoriasis, although several components remain at the stage of mechanistic research and clinical validation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →